Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Susan Prockop is an attending on the pediatric stem cell transplant program. Dr. Prockop trained in Pediatric Hematology Oncology at Memorial Sloan Kettering Cancer Center/Weill Cornell where she joined the faculty in 2004 specializing in the care of children and young adults with life-threatening blood disorders including cancer, myelodysplastic syndromes (MDS), and non-malignant disorders of blood forming and immune cells. Dr Prockop has specific expertise in the care of patients with immune deficiencies and immune dysregulation and is passionate about the importance of working with a multidisciplinary team to address the needs of each patient and their family. She conducts research that aims to improve the outcomes of children undergoing stem cell transplant and to move advances in the field of transplant, gene and cellular therapies to patients in need as rapidly as possible.
Dr. Prockop moved to Dana Farber/Boston Children’s in 2021 as the Program Director for Clinical and Translational Research and the Outpatient Clinic. In Boston she is continuing her work investigating the role of viral specific T cells in the treatment of EBV and CMV infections in patients with defects in their intrinsic immune control of these viruses. In addition, Dr. Prockop works with teams from centers across the United States and Internationally as a collaborative member of committees who share her goals. She is a principal investigator and co-investigator of several multicenter transplant, cellular therapy, and gene therapy clinical trials and is designing treatment regimens with the aim of reducing the side effects of stem cell transplantation by limiting the risk of the post-transplant complications of graft versus host disease and infection and using less toxic chemotherapy.
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions